Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Bestawros

Clinical Cardiac Electrophysiology Albuquerque, NM Medical Doctor

NPI 1699909879 CMS profile 639318

502 Elm St Ne, Albuquerque, NM 87102

Open in the dashboard

General payments

$82,211

486 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$232,211 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Michael Bestawros of Albuquerque, NM is reported in the CMS Open Payments database as having received $82,211 across 486 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $232,211 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,720 93
2024 General $16,180 68
2023 General $16,820 87
2022 General $12,474 84
2021 General $10,444 58
2020 General $585 29
2019 General $17,987 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Bestawros
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Michael Bestawros were reported at $7,720. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Michael Bestawros Clinical Cardiac Electrophysiology median Middle half National median
2019 $17,987 $2,361 $585–$8,260 $163
2020 $585 $993 $247–$4,351 $114
2021 $10,444 $1,185 $326–$4,739 $132
2022 $12,474 $2,073 $554–$6,789 $149
2023 $16,820 $2,568 $759–$8,159 $160
2024 $16,180 $2,557 $703–$7,403 $164
2025 $7,720 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $46,049 41 payments
  2. Abbott Laboratories $14,415 106 payments
  3. Boston Scientific Corporation $10,945 114 payments
  4. Biosense Webster, Inc. $5,733 125 payments
  5. Medtronic Vascular, Inc. $3,062 3 payments
  6. Medtronic, Inc. $459 17 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $360 21 payments
  8. Amgen Inc. $199 13 payments
  9. E.R. Squibb & Sons, L.L.C. $190 10 payments
  10. Atricure, Inc. $176 2 payments
  11. Other $623 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $62,600 46 payments
  2. Food and Beverage $9,527 422 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,000 4 payments
  4. Travel and Lodging $4,083 14 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $37,327 128 payments
  2. Carto 3 System $14,425 38 payments
  3. Accent Pacemaker $6,800 2 payments
  4. WATCHMAN Access System $5,876 27 payments
  5. ACCENT $3,419 6 payments
  6. FARAPULSE $3,042 5 payments
  7. Fortify Assura $2,400 4 payments
  8. WATCHMAN FLX $1,030 38 payments
  9. WATCHMAN $431 16 payments
  10. LifeVest $360 21 payments
  11. Other $4,254 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,636

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$675,856

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

44.1%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 517 $579,454
Xarelto Rivaroxaban Brand 43 $45,685
Entresto Sacubitril/Valsartan Brand 19 $21,532
Dofetilide Generic 13 $11,419
Flecainide Acetate Generic 156 $5,677
Metoprolol Succinate Generic 188 $2,668
Carvedilol Generic 168 $2,071
Amiodarone Hcl Generic 13 $1,163
Clopidogrel Clopidogrel Bisulfate Brand 68 $954
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 40 $853

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$290,334

Medicare's payments for the services billed

Medicare patients

3,287

Average age 76

Services billed

6,532

1,556 women, 1,731 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 49%
Arthritis 48%
Ischemic heart disease 46%
Heart failure 42%
Diabetes 34%
Chronic kidney disease 33%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $58
$58 43 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $38
$38 — —
ELIQUIS
  • PFIZER INC. $30
$30 517 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $29
$29 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $29
$29 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

486 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record